Opaleye Management’s LB Pharmaceuticals LBRX Stock Holding History

Opaleye Management’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,506	Closed	-$358K	–	67
2026 Q1	$358K	Buy	+14,506	New	+$335K	0.05%	53

Other funds holding LBRX

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

JP Morgan Chase

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Spruce Street Capital New York $510M AUM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Opaleye Management's LBRX Position: Q2 2026 in Review

Opaleye Management sold out of LB Pharmaceuticals (LBRX) in Q2 2026, closing a stake of 14,506 shares — an estimated $358K sold.

Opaleye Management first reported a position in LBRX in Q1 2026 and held it in 1 quarter. The position peaked at $358K in Q1 2026. 115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

Opaleye Management reported no remaining LB Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Opaleye Management sold 14,506 LB Pharmaceuticals shares in Q2 2026, an estimated $358K.
Opaleye Management first reported a position in LB Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Opaleye Management's LB Pharmaceuticals position peaked at $358K in Q1 2026.
115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.